Lumida
/CTKB
⌘K
Cytek Biosciences Inc

Cytek Biosciences Inc

CTKB
$4.62USD↓-0.43%-0.02 today

MARKET CAP

596.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$3
$6

AI Summary

Stalk
Sell NowMedium

CTKB is entrenched in a Stage 4 decline with a dominant downtrend across horizons, trading below key moving averages and pressured by a primary Support Failure pattern reinforcing bearish bias. Short-term momentum remains sideways with no oversold signals, and EMAs are acting as resistance. Execution favors selling into any rallies now.

  • ↑Q1 revenue up 6% YoY to $44.1 M, driven by service growth.
  • ↑Service revenue grew 15% YoY to $15.4 M, boosting recurring income.
  • ↓Net loss widened to $18.9 M vs. $11.4 M prior year, pressuring margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Cytek Biosciences (NASDAQ: CTKB) specializes in advanced cell analysis technology, focusing on high-performance flow cytometry solutions and services for the biopharmaceutical, academic, and clinical markets. The company is positioned as a prominent player within the rapidly evolving life sciences sector, which is seeing increased demand for innovative instrumentation and analytical technologies.

Bull says

  • ↑Q1 revenue up 6% YoY to $44.1 M, driven by service growth.
  • ↑Service revenue grew 15% YoY to $15.4 M, boosting recurring income.
  • ↑High earnings yield and strong liquidity support flexibility.
  • ↑Analyst earnings revisions positive, signaling optimistic future outlook.
  • ↑Demand for life sciences tools remains robust amid academic funding gains.
  • ↑Recurring revenue at 35% of total, up 19% YoY for stability.

Bear says

  • ↓Net loss widened to $18.9 M vs. $11.4 M prior year, pressuring margins.
  • ↓Operating expenses rose 13% YoY to $39.7 M, driven by legal costs.
  • ↓Weak profitability and negative momentum risk sustainable earnings.
  • ↓High volatility and short interest reflect bearish sentiment and price swings.
  • ↓Technical sell signals from moving averages suggest near-term downside.
  • ↓Geopolitical tensions and funding risks could hinder instrument sales.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-23-2026neutral

Transcript signals

Bull points

  • We plan to do both share repurchase and have capital available for M&A. So we think we have plenty of cash available to do both.
  • Service revenue was a bright spot, growing 24% versus Q1 of 2024.
  • We expect quarterly gross margin to improve for the balance of the year as quarterly revenue increases consistent with typical seasonal patterns.

Bear points

  • I think the CRO market postponing orders.
  • Total revenue for the first quarter of 2025 was $41.5 million, a 7.6 percent decrease compared to the first quarter of 2024.
  • Product revenue, which is instruments and reagents, decreased 18 percent versus Q1 of 2024.
Read full transcript analysis ›